ARHGEF12,which was initially identified as a fusion partner of MLL in acute myeloid leukemia, is a regulatory protein involved in the GDP/GTP exchange reaction of the Rho A and activates a Rho-GTPase-dependent signaling pathway. However, the role of ARHGEF12 in hematopoiesis remains unknown. Here, we first report that ARHGEF12 takes part in erythroid differentiation not only in erythroleukemia cell line K562 but also in zebra fish based on knockdown technology. Although primitive hematopoiesis including erythroid differentiation progressed normally, double silencing of both orthologues arhgef12a and arhgef12b in Danio rerio with morpholino caused erythropenia during definitive hematopoiesis. Meanwhile, cytology assay reveal less mature red blood cells with large and loose nuclear in morpholino injected embryos. The phenotype of blocked erythroid differentiation can be rescured by mRNA overexpression of RhoA active mutant. On the other hand, injection of mRNA transcripted from the dominant negative mutant of RhoA could replicate the phenotype of arhgef12 silencing. Antibody array screen of kinase phosphorylation suggested STAT1 and MAPK pathways downstream of Rho A may be important for erythroid differentiation in our modles.
No relevant conflicts of interest to declare.
Asterisk with author names denotes non-ASH members.